10 Best New Stocks to Invest In According to Hedge Funds

7. Mineralys Therapeutics Inc. (NASDAQ:MLYS)

Number of Hedge Fund Holders: 61

Mineralys Therapeutics Inc. (NASDAQ:MLYS) is one of the best new stocks to invest in according to hedge funds. On March 24, Mineralys Therapeutics appointed Jeffrey A. Munsie as Chief Legal Officer to oversee the company’s legal and compliance functions. Munsie brings 25 years of biopharmaceutical experience to the role, having previously served in leadership positions at Orbital Therapeutics, Concert Pharmaceuticals, and Merrimack Pharmaceuticals.

His background spans the full drug development lifecycle, from preclinical stages through commercialization, which the company views as essential for its next phase of growth. In his new role, Munsie will provide strategic counsel as Mineralys Therapeutics Inc. (NASDAQ:MLYS) advances its lead candidate, lorundrostat, which targets hypertension and related conditions like chronic kidney disease and obstructive sleep apnea.

CEO Jon Congleton highlighted Munsie’s proven track record in handling intellectual property strategy, transactions, and compliance as a key asset for the organization. Munsie, a Harvard Law School graduate, expressed his commitment to helping bring the company’s treatments to patients affected by dysregulated aldosterone.

Mineralys Therapeutics Inc. (NASDAQ:MLYS) develops therapeutics that target illnesses caused by dysregulated aldosterone. It is working on the development of lorundrostat, an aldosterone synthase inhibitor for cardiorenal conditions. These include chronic kidney disease, hypertension, and obstructive sleep apnea.